US EditionA Popular Thyroid Drug Has Been Withdrawn. a Worrying Inconsistency Has Been Discovered
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
The Chief Pharmaceutical Inspectorate (GPI) has recalled a batch of Euthyrox N, a popular medication used to treat thyroid conditions. The reason for the recall is anomalies in the active ingredient content. This particular batch may contain excessive amounts of levothyroxine, which can lead to hormonal imbalances and health complications.
A batch of the thyroid medication Euthyrox N has been withdrawn from circulation. The product was found to contain an incorrect active ingredient. The Chief Pharmaceutical Inspectorate announced that the decision is immediately enforceable. Patients are urged not to take the medication from this batch.
The Chief Pharmaceutical Inspector has ordered the withdrawal of Euthyrox N 25, 25 µg, from the market. This concerns the G02PXT batch in packages of 100 tablets with an expiration date of February 29, 2028. The reason is an incorrect result obtained during testing for the active substance. According to the Chief Pharmaceutical Inspector, this may pose a risk to patient health.
The Chief Pharmaceutical Inspector has withdrawn a batch of Euthyrox N from sale nationwide. This is a popular medication used to treat thyroid conditions. Why was this decision made?
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
